aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Last trade$4.96
Day change-$0.28 (-5.34%)
Day range$4.64 – $5.52
Volume116,198
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.36M
Price / earnings
—
Price / book
0.39×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.01×
Profitability
Earnings per share
-$20.92
Return on assets
-89.16%
Return on equity
-156.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
3.05×
Quick ratio
3.05×
Cash ratio
0.8×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ATYR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$190K
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$190K
$0
$0
$0
Selling, general and administrative
$8.35M
$4.13M
$4.12M
$3.91M
$4.81M
$4.93M
$3.96M
$3.59M
Research and development
$10.45M
$6.75M
$7.32M
$10.89M
$22.13M
$15.38M
$11.81M
$12.23M
Total operating expenses
$18.79M
$10.88M
$11.44M
$14.8M
$26.94M
$20.31M
$15.77M
$15.82M
Operating income
-$18.79M
-$10.88M
-$11.44M
-$14.8M
-$26.75M
-$20.31M
-$15.77M
-$15.82M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$18.26M
-$10.31M
-$10.79M
-$13.96M
-$25.75M
-$19.53M
-$14.88M
-$14.97M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$18.26M
-$10.31M
-$10.79M
-$13.96M
-$25.75M
-$19.53M
-$14.88M
-$14.97M
Net income attributable to common shareholders
-$18.26M
-$10.31M
-$10.79M
-$13.96M
-$25.74M
-$19.53M
-$14.88M
-$14.97M
EBITDA
-$18.62M
-$10.71M
-$11.27M
-$14.63M
-$26.58M
-$20.15M
-$15.61M
-$15.65M
Basic earnings per share
-$7.43
-$4.40
-$4.40
-$5.69
-$10.60
-$8.80
-$6.80
-$7.22
Diluted earnings per share
-$7.43
-$4.40
-$4.40
-$5.69
-$10.60
-$8.80
-$6.80
-$7.22
Recent news
Company coverage with links to the original publishers.
The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.
aTyr Pharma (Nasdaq: ATYR), a clinical-stage biotechnology company, announced a 1-for-40 reverse stock split effective October 28, 2026, to comply with Nasdaq Capital Market's minimum bid price requirement. The split will reduce outstanding shares from approximately 100.5 million to 2.5 million, with trading resuming on a split-adjusted basis on October 29, 2026 under the same ticker symbol.
aTyr Pharma announced it will advance efzofitimod development in pulmonary sarcoidosis following a Type C FDA meeting. The company plans to submit an IND in June 2026 for a Phase 3 study using FVC as primary endpoint and KSQ-Lung as secondary endpoint. The company ended Q1 2026 with $68.3 million in cash and is on track to complete enrollment in its Phase 2 SSc-ILD study in H1 2026.
The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.
Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.